Top

Cancer Causes & Control

Published in:

01-08-2009 | Original Paper

Risk of cancer among rheumatoid arthritis patients in California

Authors: Arti Parikh-Patel, Richard H. White, Mark Allen, Rosemary Cress

Published in: Cancer Causes & Control | Issue 6/2009

Abstract

Objective

The objective of this retrospective cohort study was to evaluate cancer risk among rheumatoid arthritis (RA) patients in California.

Methods

The study cohort derived from statewide patient discharge records was followed via linkage with cancer registry data over the period 1991–2002. Age and sex adjusted standardized incidence ratios (SIRs) and 95% confidence intervals were calculated to compare observed to expected numbers of cancers based on age, race, and sex specific incidence rates in the California population.

Results

Among the 84,475 RA patients, who were observed for 405,540 person-years, 5,533 incident cancers were diagnosed during the observation interval. The risk of developing lymphohematopoietic cancer was significantly higher in the cohort for both sexes. Males had significantly higher risks of lung, liver, and esophageal cancer, but a lower risk of prostate cancer. Females were at significantly decreased risk for several cancers including breast, ovary, uterus, cervix, and melanoma, with the risk reduction ranging from 15 to 57% lower than the general population. Hispanics had increased risks of leukemia, vagina/vulva, lung, and liver cancers.

Conclusion

Studies investigating the mechanisms that underlie the reported associations between RA and specific cancer types are needed.

Hochberg MC, Spector TD (1990) Epidemiology of rheumatoid arthritis: update. Epidemiol Rev 12:247–252PubMed

Harris ED (1997) Clinical features of rheumatoid arthritis. In: Kelly WN, Harris ED, Ruddy S, Sledge CB (eds) Textbook of rheumatology, 5th edn. WB Saunders, Philadelphia, pp 895–922

Abu-Shakra M, Buskila D, Shoenfeld Y (2000) Rheumatoid arthritis and cancer. In: Gershwin ME, Shoenfeld Y (eds) Cancer and autoimmunity. Elsevier, Amsterdam, pp 19–30

Isomaki HA, Hakulinene T, Joutsenlahti U (1978) Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31:691–696. doi:10.1016/0021-9681(78)90071-1 PubMedCrossRef

Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami H, Hacker DG et al (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307–311. doi:10.1093/jnci/85.4.307 PubMedCrossRef

Katusic S, Beard CM, Kurland LT, Weis JW, Bergstralh (1985) Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 78(Suppl 1A):50–55. doi:10.1016/0002-9343(85)90246-3 PubMedCrossRef

Hakulinen T, Isomaki H, Knekt P (1985) Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 78(suppl 1A):29–32. doi:10.1016/0002-9343(85)90242-6 PubMedCrossRef

Symmons DP, Ahern M, Bacon PA, Hawkins CF, Amlot PL, Jones EL et al (1984) Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases. Ann Rheum Dis 43:132–135. doi:10.1136/ard.43.2.132 PubMedCrossRef

Seidenfeld AM, Smythe HA, Ogryzlo MA, Urowitz MB, Dotten DA (1984) Acute leukemia in rheumatoid arthritis treated with cytotoxic agents. J Rheumatol 11:586–587PubMed

10.

Taylor HG, Nixon N, Sheeran TP, Dawes PT (1989) Rheumatoid arthritis and chronic lymphocytic leukemia. Clin Exp Rheumatol 7:529–532PubMed

11.

Fam AG, Lewis AJ, Cowan DH (1981) Multiple myeloma and amyloid bone lesions complicating rheumatoid arthritis. J Rheumatol 8:845–850PubMed

12.

Shenberger KN, Schned AR, Taylor TH (1984) Rheumatoid disease and bronchogenic carcinoma-case report and review of the literature. J Rheumatol 13:909–911

13.

Gridley G, Klippel JH, Hoover RN, Fraumeni JF Jr (1994) Incidence of cancer among men with the Felty syndrome. Ann Intern Med 120(1):35–39PubMed

14.

Cibere J, Sibley J, Haga M (2001) Systemic lupus erythematosus and the risk of malignancy. Lupus 10(6):394–400. doi:10.1191/096120301678646128 PubMedCrossRef

15.

Kauppi M, Isomaki H (1997) Elevated incidence of hematologic malignancies in patients with Sjogren’s syndrome compared with patients with rheumatoid arthritis. Cancer Causes Control 1997:201–204CrossRef

16.

Thun MJ, Nambodiri MM, Heathn CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593–1596PubMed

17.

Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, et al. (2008) Anti-TNF therapy in RA and risk of malignant lymphomas relative risks and time-trends in the Swedish Biologics Register. Ann Rheum Dis

18.

Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L (2004) Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 16(3):254–261. doi:10.1097/00002281-200405000-00014 PubMedCrossRef

19.

Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54(3):692–701. doi:10.1002/art.21675 PubMedCrossRef

20.

Kinlen LJ (1992) Malignancy in autoimmune diseases. J Autoimmun 5(Suppl A):363–371. doi:10.1016/0896-8411(92)90055-U PubMedCrossRef

21.

Silman AJ, Petrie J, Hazleman B, Evans SJ (1988) Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 47:988–992. doi:10.1136/ard.47.12.988 PubMedCrossRef

22.

Tennis P, Andrews E, Bombardier C, Wang Y, Strand L, West R et al (1993) Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the province of Saskatchewan, Canada. J Clin Epidemiol 46(7):685–695. doi:10.1016/0895-4356(93)90049-7 PubMedCrossRef

23.

Services USDoHaH (ed) (2000) ICD-9-CM: international classification of diseases, 9th revision, clinical modification, 6th edn. Washington, DC

24.

Cancer Reporting in California: Standards for Automated Reporting (1997) California cancer reporting system standards, vol II. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA

25.

Cancer Reporting in California: Data Standards for Regional Registries and California Cancer Registry (1997) California cancer reporting system standards, vol III. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA

26.

Cancer Reporting in California: Reporting Procedures for Physicians (1998) California cancer reporting system standards, vol IV. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA

27.

Cancer Reporting in California: Abstracting and Coding Procedures for Hospitals (1997) California cancer reporting system standards, vol I. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA

28.

Chen VW, Howe HL, Wu XC (2000) Cancer in North America, 1993–1997 vol I. Incidence. North American Association of Central Cancer Registries, Springfield, IL

29.

Seiffert JE, Price WT, Gordon B (1990) The California tumor registry: a state-of-the-art model for a regionalized, automated, population-based registry. Top Health Rec Manage 11:59–73PubMed

30.

Vality Technology Inc. (1999) Integrity program: data reengineering environment software, ver 3.3. Vality Technology Inc., Boston, MA

31.

Allen M (2001) Validation of OSHPD and CCR insurance status. In: California association of central cancer registries technical conference, 25 September, 2001, Riverside, CA

32.

Breslow NE, Day NE (1987) Statistical methods in cancer research. Vol II. The design and analysis of cohort studies. International Agency for Research on Cancer, Lyon

33.

Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A(10):1753–1757. doi:10.1016/0959-8049(96)00210-9 PubMedCrossRef

34.

Prior P (1985) Cancer and rheumatoid arthritis: epidemiologic considerations. Am J Med 78(Suppl 1A):15–21. doi:10.1016/0002-9343(85)90240-2 PubMedCrossRef

35.

Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88(3):497–502. doi:10.1002/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-JPubMedCrossRef

36.

Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case–control study. Br Med J 317(7152):180–181

37.

Wolfe F (1998) Inflammatory activity but not prednisone or methotrexate use predicts non-Hodgkin’s lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients [abstract 931]. Arthritis Rheum S188

38.

Baker GL, LE Kahl, Zee BC, Stolzer BL, Agarwal AK, Medsger TA Jr (1987) Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case–control follow-up study. Am J Med 83(1):1–9. doi:10.1016/0002-9343(87)90490-6 PubMedCrossRef

39.

Kinlen LJ (1985) Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatments. Am J Med 78(suppl 1A):44–49. doi:10.1016/0002-9343(85)90245-1 PubMedCrossRef

40.

Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB (1991) Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. Rheumatoid arthritis azathioprine registry steering committee. J Rheumatol 8(6):809–814

41.

Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A et al (1995) Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 38(8):1120–1127. doi:10.1002/art.1780380815 PubMedCrossRef

42.

Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275–2285. doi:10.1001/jama.295.19.2275 PubMedCrossRef

43.

Beauparlant P, Papp K, Haraoui B (1999) The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:148–158. doi:10.1016/S0049-0172(99)80026-2 PubMedCrossRef

44.

Starkebaum G (2001) Rheumatoid arthritis, methotrexate, and lymphoma: risk substitution, or cat and mouse with Epstein-Barr virus? J Rheumatol 28(12):2573–2575PubMed

45.

Helmers R, Galvin J, Hunninghake GW (1991) Pulmonary manifestations associated with rheumatoid arthritis. Chest 100(1):235–238. doi:10.1378/chest.100.1.235 PubMedCrossRef

46.

Hernandez Avila M, Liang MH, Willett WC, Stampfer MJ, Colditz GA, Rosner B et al (1990) Reproductive factors, smoking, and the risk for rheumatoid arthritis. Epidemiology 1(4):285–291PubMedCrossRef

47.

Silman AJ, Newman J, MacGregor AJ (1996) Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 39(5):732–735. doi:10.1002/art.1780390504 PubMedCrossRef

48.

Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR (1994) Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 5(5):525–532PubMed

49.

Baron JA (2003) Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 37:1–24. doi:10.1159/000071364 PubMedCrossRef

50.

Chakravarty EF, Genovese MC (2004) Associations between rheumatoid arthritis and malignancy. Rheum Dis Clin North Am 30(2):271–284. doi:10.1016/j.rdc.2004.01.007 ViPubMedCrossRef

51.

Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, Hall S et al (2008) Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 59(6):794–799. doi:10.1002/art.23716 PubMedCrossRef

52.

Abasolo L, Judez E, Descalzo MA, Gonzalez-Alvaro I, Jover JA, Carmona L (2008) Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 37(6):388–397. doi:10.1016/j.semarthrit.2007.08.006 PubMedCrossRef

53.

Gao J, Niwa K, Sun W, Takemura M, Lian Z, Onogi K et al (2004) Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci 95(11):901–907. doi:10.1111/j.1349-7006.2004.tb02200.x PubMedCrossRef

54.

Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R (2003) Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3:28. doi:10.1186/1471-2407-3-28 PubMedCrossRef

55.

Mahmud SM, Tanguay S, Begin LR, Franco EL, Aprikian AG (2006) Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev 15(2):158–164. doi:10.1097/01.cej.0000197451.02604.25 PubMedCrossRef

56.

Moorman PG, Grubber JM, Millikan RC, Newman B (2003) Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 14(10):915–922. doi:10.1023/B:CACO.0000007973.59863.66 PubMedCrossRef

57.

Pereg D, Lishner M (2005) Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 258(2):115–123. doi:10.1111/j.1365-2796.2005.01519.x PubMedCrossRef

58.

Stock DC, Groome PA, Siemens DR, Rohland SL, Song Z (2008) Effects of non-selective non-steroidal anti-inflammatory drugs on the aggressiveness of prostate cancer. Prostate

59.

Cevik R, Em S, Gur A, Nas K, Sarac AJ, Colpan L (2004) Sex and thyroid hormone status in women with rheumatoid arthritis: are there any effects of menopausal state and disease activity on these hormones? Int J Clin Pract 58(4):327–332. doi:10.1111/j.1368-5031.2004.00005.x PubMedCrossRef

60.

Cutolo M, Villaggio B, Craviotto C, Pizzorni C, Seriolo B, Sulli A (2002) Sex hormones and rheumatoid arthritis. Autoimmun Rev 1(5):284–289. doi:10.1016/S1568-9972(02)00064-2 PubMedCrossRef

61.

Kuiper S, van Gestel AM, Swinkels HL, de Boo TM, da Silva JA, van Riel PL (2001) Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. J Rheumatol 28(8):1809–1816PubMed

62.

Masi AT (1995) Sex hormones and rheumatoid arthritis: cause or effect relationships in a complex pathophysiology? Clin Exp Rheumatol 13(2):227–240PubMed

63.

Katz JN, Barrett J, Liang MH, Bacon AM, Kaplan H, Kieval RI et al (1997) Sensitivity and positive predictive value of medicare part B physician claims for rheumatologic diagnoses and procedures. Arthritis Rheum 40(9):1594–1600. doi:10.1002/art.1780400908 PubMedCrossRef

64.

Brooks PM (1992) Rheumatic manifestations of neoplasia. Curr Opin Rheumatol 4(1):90–93PubMed

65.

Butler RC, Thompson JM, Keat AC (1987) Paraneoplastic rheumatic disorders: a review. J R Soc Med 80(3):168–172PubMed

Title: Risk of cancer among rheumatoid arthritis patients in California
Authors: Arti Parikh-Patel
Richard H. White
Mark Allen
Rosemary Cress
Publication date: 01-08-2009
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 6/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-009-9298-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2009

Relationship between cardiopulmonary mortality and cancer risk and quantitative exposure to polycyclic aromatic hydrocarbons, fluorides, and dust in two prebake aluminum smelters

Lifestyle factors and serum androgens among 636 middle aged men from seven countries in the European Prospective Investigation into Cancer and Nutrition (EPIC)

Dietary fiber and stomach cancer risk: a case–control study from Italy

Case–control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany

Dose–response meta-analysis of silica and lung cancer

Viral and non-viral risk factors for non-Hodgkin’s lymphoma in Egypt: heterogeneity by histological and immunological subtypes

Keynote webinar | Spotlight on antibody–drug conjugates in cancer